文献速递脊柱关节炎

银屑病关节炎的靶向全身治疗:短期关节、皮肤、附着点和指炎结局的系统综述与比较合成

Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.
PubMed 文献 · RMD Open · 2022-01-01

该系统综述纳入46项RCT,采用贝叶斯网络Meta分析比较靶向DMARDs对活动性PsA的疗效与安全性。IL-17A/IL-17RA抑制剂和guselkumab在PASI应答上优于抗TNF,在附着点和指炎消退上与阿达木单抗相似,支持根据主要临床表型选择药物。

要点

  • IL-17A/IL-17RA抑制剂和guselkumab在皮肤表现上优于抗TNF。
  • IL-17抑制剂与阿达木单抗在附着点和指炎消退上疗效相似。
  • 英夫利西单抗(联用或不联用甲氨蝶呤)、certolizumab 400mg每4周和tildrakizumab的DAE率最高。

核心结论

  • 尽管ACR应答疗效相似,IL-17A和IL-17RA抑制剂及guselkumab在皮肤表现、附着点和指炎方面优于抗TNF,支持根据主要临床表型选择药物。

研究设计与样本

  • 系统综述识别RCT,采用贝叶斯网络Meta分析比较疗效(ACR应答、PASI应答、附着点和指炎消退)和安全性(因不良事件停药)。
  • 网络Meta分析纳入46项研究,亚组分析探索既往生物制剂暴露对ACR应答的影响。

主要发现

  • 某些抗TNF在ACR应答上可能数值上优于IL抑制剂但未达显著,而在PASI应答上较差。
  • 按既往bDMARD暴露亚组分析后,bDMARDs间ACR应答的显著差异较少。
  • guselkumab和IL-17A或IL-17RA抑制剂(brodalumab、ixekizumab、secukinumab)在PASI应答上最佳。
  • 这些IL抑制剂和阿达木单抗在附着点和指炎消退上疗效相似。
  • 英夫利西单抗(联用或不联用甲氨蝶呤)、certolizumab 400mg每4周和tildrakizumab的DAE率最高;阿巴西普、golimumab和IL抑制剂最低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Randomised controlled trials (RCTs) have compared biological and targeted systemic disease-modifying antirheumatic drugs (DMARDS) against placebo in psoriatic arthritis (PsA); few have compared them head to head. OBJECTIVES: To compare the efficacy and safety of all evaluated DMARDs for active PsA, with a special focus on biological DMARDs (bDMARDs) licensed for PsA or psoriasis. METHODS: A systematic review identified RCTs and Bayesian network meta-analysis (NMA) compared treatments on efficacy (American College of Rheumatology (ACR) response, Psoriasis Area and Severity Index (PASI) response, resolution of enthesitis and dactylitis) and safety (patients discontinuing due to adverse events (DAE)) outcomes. Subgroup analyses explored ACR response among patients with and without prior biological therapy exposure. RESULTS: The NMA included 46 studies. Results indicate that some tumour necrosis factor inhibitors (anti-TNFs) may perform numerically, but not significantly, better than interleukin (IL) inhibitors on ACR response but perform worse on PASI response. Few significant differences between bDMARDs on ACR response were observed after subgrouping for prior bDMARD exposure. Guselkumab and IL-17A or IL-17RA inhibitors-brodalumab, ixekizumab, secukinumab-were best on PASI response. These IL-inhibitors and adalimumab were similarly efficacious on resolution of enthesitis and dactylitis. Infliximab with and without methotrexate, certolizumab 400 mg every 4 weeks and tildrakizumab showed the highest rates of DAE; abatacept, golimumab and the IL-inhibitors, the lowest. CONCLUSIONS: Despite similar efficacy for ACR response, IL-17A and IL-17RA inhibitors and guselkumab offered preferential efficacy to anti-TNFs in skin manifestations, and for enthesitis and dactylitis, thereby supporting drug selection based on predominant clinical phenotype.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. McInnes IB, Sawyer LM, Markus K, et al. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open. 2022. PMID: 35321874. doi:10.1136/rmdopen-2021-002074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。